Fidelity Investments’s Avalo Therapeutics AVTX Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q3
$80.5M Buy
5,250,181
+149,965
+3% +$2.76M ﹤0.01% 1296
2026
Q2
$94.3M Buy
5,100,216
+2,220,735
+77% +$35.1M ﹤0.01% 1243
2026
Q1
$43M Buy
2,879,481
+2,659,181
+1,207% +$41.6M ﹤0.01% 1494
2025
Q4
$4M Buy
+220,300
New +$3.72M ﹤0.01% 2357
2024
Q4
– Sell
-1
Closed -$9 – 5544
2024
Q3
$9 Sell
1
-1
-50% -$10 ﹤0.01% 5434
2024
Q2
$25 Buy
+2
New +$26 ﹤0.01% 5149
2023
Q1
– Hold
0
– -$66 – 5270
2022
Q4
– Hold
0
– – – 4916
2022
Q3
– Hold
0
– – – 4933
2022
Q2
– Hold
0
– – – 4835
2022
Q1
– Hold
0
– – – 4981

Other funds holding AVTX

Fidelity Investments's AVTX Position: Q3 2026 in Review

Fidelity Investments increased its Avalo Therapeutics (AVTX) stake by 2.9% in Q3 2026, buying an estimated $2.76M and bringing the position to 5,250,181 shares worth $80.5M. The position accounts for ﹤0.01% of the portfolio, ranked #1296.

Fidelity Investments first reported a position in AVTX in Q2 2024 and has held it in 6 quarters since. The position peaked at $94.3M in Q2 2026. 148 funds tracked by Wall St. Rank hold AVTX as of Q3 2026.

  • Fidelity Investments held 5,250,181 shares of Avalo Therapeutics worth $80.5M as of Q3 2026.
  • Fidelity Investments bought 149,965 Avalo Therapeutics shares in Q3 2026, an estimated $2.76M.
  • Avalo Therapeutics made up ﹤0.01% of Fidelity Investments's portfolio in Q3 2026, its #1296 holding.
  • Fidelity Investments first reported a position in Avalo Therapeutics in Q2 2024 and has held it in 6 quarters since.
  • Fidelity Investments's Avalo Therapeutics position peaked at $94.3M in Q2 2026.
  • 148 funds tracked by Wall St. Rank held Avalo Therapeutics as of Q3 2026.

Based on Fidelity Investments's 13F filing for Q3 2026, filed 10 Nov 2026.